Erratum to Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma[J Cancer Res Clin Oncol, (2012), 138, 1717, 1725, 10.1007/s00432-012-1219-x];Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 10, 2012, Pages 1717-1725

  Jin, Ying ^a,b   Cai, Xiu Yu ^b   Shi, Yan Xia ^b   Xia, Xi Ya ^b   Cai, Yu Chen ^b   Cao, Ye ^b   Zhang, Wei Dong ^b   Hu, Wei Han ^b   Jiang, Wen Qi ^b  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Comparison of five cisplatin based regimens; Metastatic nasopharyngeal carcinoma; Overall survival; Palliative chemotherapy; Progression free survival

Indexed keywords

ANTIEMETIC AGENT; BLEOMYCIN; CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; FLUOROURACIL; GEMCITABINE; PACLITAXEL; SEROTONIN ANTAGONIST;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HUMAN; INFECTION; LIVER METASTASIS; LONG TERM SURVIVAL; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NASOPHARYNX CARCINOMA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84866732807     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-1926-1     Document Type: Erratum

References (27)

1. An X, Wang FH, Ding PR et al (2011) Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer 117:3750-3757
2. Au E, Ang PT (1994) A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol 5(1):87-89
3. Azli N, Fandi A, Bachouchi M et al (1995) Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer J Sci Am 1(3):222-229
4. Bensouda Y, Kaikani W, Ahbeddou N et al (2011) Treatment for metastatic nasopharyngeal carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis 128(2):79-85
5. Boussen H, Cvitkovic E, Wendling JL et al (1991) Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil. J Clin Oncol 9(9):1675-1681
6. Chang ET, Adami HO (2006) The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 15(10):1765-1777
7. Chiesa F, De Paoli F (2001) Distant metastases from nasopharyngeal cancer. ORL J Otorhinolaryngol Relat Spec 63(4):214-216
8. Chua DT, Wei WI, Wong MP, Sham JS, Nicholls J, Au GK (2008) Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck 30(7):863-867
9. Ciuleanu TE, Fountzilas G, Ciuleanu E, Plataniotis M, Todor N, Ghilezan N (2004) Paclitaxel and carboplatin in relapsed or metastatic nasopharyngeal carcinoma: a multicenter phase II study. J BUON 9(2):161-165
10. Ciuleanu E, Irimie A, Ciuleanu TE, Popita V, Todor N, Ghilezan N (2008) Capecitabine as salvage treatment in relapsed nasopha-ryngeal carcinoma: a phase II study. J BUON 13(1):37-42
11. Foo KF, Tan EH, Leong SS et al (2002) Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol 13(1):150-156
12. He XY, Hu CS, Ying HM, Wu YR, Zhu GP, Liu TF (2010) Paclitaxel with cisplatin in concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol 267(5):773-778
13. Kam MK, Leung SF, Zee B et al (2007) Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 25(31):4873-4879
14. Lee AW, Poon YF, Foo W et al (1992) Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 23(2):261-270
15. Lin JT, Lai GM, Chang TH et al (2012) Chemotherapy with modified docetaxel, cisplatin, and 5-Fluorouracil in patients with meta-static head and neck cancer. Adv Ther 29(1):71-77
16. Liu MT, Hsieh CY, Chang TH, Lin JP, Huang CC, Wang AY (2003) Prognostic factors affecting the outcome of nasopharyngeal carcinoma. Jpn J Clin Oncol 33(10):501-508
17. Ma BB, Chan AT (2005) Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer 103(1):22-31
18. Ma BB, Tannock IF, Pond GR, Edmonds MR, Siu LL (2002) Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer 95(12):2516-2523
19. Ngan RK, Yiu HH, Lau WH et al (2002) Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopha-ryngeal carcinoma: report of a phase II study. Ann Oncol 13(8):1252-1258
20. Ngeow J, Lim WT, Leong SS et al (2011) Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. Ann Oncol 22(3):718-722
21. Ong YK, Heng DM, Chung B et al (2003) Design of a prognostic index score for metastatic nasopharyngeal carcinoma. Eur J Cancer 39(11):1535-1541
22. Sakata K, Aoki Y, Karasawa K et al (1994) Wide variation of probability of local failure and distant metastasis among various stages of patients with nasopharyngeal carcinoma. Strahlenther Onkol 170(4):218-224
23. Schwarz LR (1996) Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyn-geal carcinoma. Cancer 78(3):566-567
24. Su WC, Chen TY, Kao RH, Tsao CJ (1993) Chemotherapy with cisplatin and continuous infusion of 5-fluorouracil and bleomy-cin for recurrent and metastatic nasopharyngeal carcinoma in Taiwan. Oncology 50(4):205-208
25. Tao Y, Bidault F, Bosq J, Bourhis J (2008) Distant metastasis of undifferentiated carcinoma of nasopharyngeal type. Onkologie 31(11):574-575
26. Wang TL, Tan YO (1991) Cisplatin and 5-fluorouracil continuous infusion for metastatic nasopharyngeal carcinoma. Ann Acad Med Singap 20(5):601-603
27. Yu MC, Yuan JM (2002) Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 12(6):421-429